Oculis' Phase 2b trial shows positive results for its anti-TNFα eye drop, licaminlimab, in treating dry eye disease.
Oculis' Phase 2b RELIEF trial found positive results for its novel anti-TNFα eye drop, licaminlimab, in treating dry eye disease. The treatment showed efficacy and safety improvements, with more pronounced effects in the TNFR1 genetic biomarker population. Oculis plans to finalize Phase 3 development plans following an End-of-Phase 2 meeting with the FDA, aiming to transform the treatment paradigm of dry eye disease with its precision medicine approach.
June 10, 2024
4 Articles